Keppra Related Published Studies
Well-designed clinical trials related to Keppra (Levetiracetam)
Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. [2009.07]
Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. [2009.07]
Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. [2009.06]
Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. [2009.06]
A prospective pilot study of levetiracetam for body dysmorphic disorder. [2009.05]
Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. [2009.05]
Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study. [2009.04]
Pharmacokinetics of levetiracetam XR 500mg tablets. [2009.04]
Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. [2009.03]
Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. [2009.03]
The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. [2009.03]
Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. [2009.03]
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. [2009.03]
Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures. [2009.01.29]
Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. [2009]
Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. [2009]
Bioequivalence of two formulations of levetiracetam. [2008.11]
Levetiracetam in absence epilepsy. [2008.11]
Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. [2008.09.12]
Effect of levetiracetam on the postmastectomy pain syndrome. [2008.08]
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. [2008.07.24]
Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. [2008.06]
Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. [2008.04]
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. [2008.02.19]
Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. [2008.02]
Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. [2008.02]
Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study. [2008.02]
The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. [2008]
Levetiracetam and bleeding disorders. [2007.12]
Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. [2007.11.27]
Levetiracetam is not effective for essential tremor. [2007.11]
Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. [2007.11]
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. [2007.10.30]
Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. [2007.10]
Impact of levetiracetam on mood and cognition during prednisone therapy. [2007.10]
A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. [2007.09.15]
Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. [2007.05]
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. [2007.02.06]
Influence of levetiracetame on ictal and postictal EEG in patients with partial seizures. [2006.12]
Assessment of a dose-response relationship of levetiracetam. [2006.09]
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. [2006.07]
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. [2006.06.13]
Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. [2006.05]
Specific effect of levetiracetam in experimental human pain models. [2006.04]
Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA). [2006.03]
Effects of levetiracetam on nocturnal sleep and daytime vigilance in healthy volunteers. [2006.01]
Efficacy and Safety of Levetiracetam (up to 2000 mg/day) in Taiwanese Patients with Refractory Partial Seizures: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. [2006.01]
Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. [2006]
Effects of levetiracetam on sleep in normal volunteers. [2005.11]
Levetiracetam in social phobia: a placebo controlled pilot study. [2005.09]
Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. [2005.05]
The effect of levetiracetam on essential tremor. [2005.03.22]
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. [2005.03]
Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. [2005.03]
Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function--a TMS study. [2004.11]
Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. [2004.11]
Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. [2004.10]
Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. [2003.12]
Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. [2003.05]
A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. [2003.04]
Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. [2003.02]
Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. [2003.02]
The effects of levetiracetam on objective and subjective sleep parameters in healthy volunteers and patients with partial epilepsy. [2002.09]
Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. [2002.07]
Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. [2002.05]
Levetiracetam: a different approach to the pharmacotherapy of epilepsy. [2002.02]
Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. [2002.01]
Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. [2001.11]
Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. [2001.08]
Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. [2000.12]
Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. [2000.10]
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. [2000.09]
Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. [2000.08]
Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. [2000.07.25]
Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. [2000.07]
A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. [2000.03]
Well-designed clinical trials possibly related to Keppra (Levetiracetam)
The anaesthetic and intensive care of status epilepticus. [2007.04]
[Use of antiepileptic drugs in bipolar disorder] [2006.01]
2005 AES Annual Course: Evidence Used to Treat Women with Epilepsy. [2006]
Other research related to Keppra (Levetiracetam)
Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. [2009.08]
Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome. [2009.08]
Levetiracetam decreases the seizure activity and blood-brain barrier permeability in pentylenetetrazole-kindled rats with cortical dysplasia. [2009.07.24]
Levetiracetam induced interstitial nephritis and renal failure. [2009.07]
Role of intravenous levetiracetam in acute seizure management of children. [2009.07]
Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. [2009.07]
Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. [2009.06]
Epileptic negative myoclonus: SPECT, PET, and video/EEG studies and the dramatic effects of levetiracetam. [2009.04]
Charles Bonnet syndrome disappearing with carbamazepine and valproic acid but not with levetiracetam. [2009.03]
Levetiracetam for seizures in children with brain tumors and other cancers. [2009.02]
Levetiracetam improves intention tremor in fragile x-associated tremor/ataxia syndrome. [2009.01]
Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study. [2008.12]
The efficacy and tolerability of Levetiracetam as an add-on therapy in patients with startle epilepsy. [2008.10]
Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. [2008.09.15]
Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. [2008.08.26]
Levetiracetam in continuous spike waves during slow-wave sleep syndrome. [2008.08]
Antinociceptive efficacy of levetiracetam in a mice model for painful diabetic neuropathy. [2008.08]
Levetiracetam in patients with epilepsy and chronic liver disease: observations in a case series. [2008.07]
The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. [2008.07]
Thrombocytopenia during levetiracetam therapy. [2008.07]
Prolonged neurophysiologic effects of levetiracetam after oral administration in humans. [2008.07]
Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. [2008.07]
|
